Featured Speakers

• 

  Richard WoosterVP, Head of Cancer Metabolism GSK

• 

  Chi DangDirector Abramson Cancer Center

• 

  Paul SmithPrincipal Scientist - Cancer Biosciences, Oncology iMed AstraZeneca

• 

  Georgia HatzivassiliouScientist Genentech

About

With millions of dollars of investment from pharmaceutical giants, this meeting focuses on the exciting research field that everyone is watching: cancer metabolism.

Given the pharmaceutical industry’s heavy investment into the research of cancer metabolism, now is the perfect time to come together to cash in on the benefits of cancer starving drugs. Seize your chance to take part in the fast growing community which is translating the Warburg phenomenon into a new generation of cancer therapies.

Sharing strategies and approaches to drug discovery will play a vital step in your company’s progression of metabolic targeting cancer drugs. With large pharma and leading biotechs now ready to reveal those techniques there has never been a meeting so focused on pushing metabolic targeting drugs into the clinic and through to the market.

With the agenda designed by cutting edge research with experts at GSK, AstraZeneca, Genentech, Myrexis, Cornerstone and Warburg Glycomed, the World Cancer Metabolism summit is unchallenged in its industry relevance. It is designed to be specific and relevant to cancer metabolism and will deliver solutions to current issues faced by drug developers. 

What’s on the agenda?

This meeting includes frank discussions, networking sessions and insightful presentations, to provide all the elements needed to ensure your pipeline’s success.

• Enhance your current approaches in target identification and validation by exploring the latest strategies employed by leading biotechs such as Agios, Myrexis and  Forma Therapeutics
• Improve your patient stratification and patient selection by realising the potential of advanced imaging technology with Tavargenix and discussing techniques with AstraZeneca and Kancera
• Overcome the challenges created by metabolic redundancy to assess how this can benefit your pipeline with Warburg Glycomed
• Learn how to more accurately predict results in clinical trials by overcoming limitations of traditional pre-clinical models
• Drive the success of personalized cancer treatment with new strategies for diagnostics from the Kimmel Cancer Center
• Advance your bioinformatics approaches using public data resources for studying tumor metabolism with GSK
  
• Improve your company’s capabilities to deliver metabolic targeting drugs to the market by revising the optimal design of clinical trials

Why attend?

This meeting will be your only to chance to hear from the industry leaders such as GSK, Agios, Forma Therapeutics, Genentech, Warburg Glycomed and Myrexis about the approaches and strategies that they use when developing these drugs. You will learn how to make the most out of your research whilst building long-lasting business relationships through dedicated networking sessions.

You will also receive personalized advice and guidance on achieving success in pre clinical and clinical development of metabolic targeting drugs. As well as our main programme, our pre-conference workshops are a fantastic chance to get the information and contacts you need through a small, high-level and interactive discussion.

What’s next? 

1. Download the agenda to see more detail on the topics for coverage.

2. Stay updated by joining the LinkedIn community. Search groups for “Cancer Metabolism Forum”

3. Something you want to share; white papers, articles or interested in speaking? Then let us know... just email any questions to info@hansonwade.com 

4. Don't waste time! If you're planning on joining us then get the best rates by securing your place now - Book online or call +1 212 537 5898.